Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer

Mostrar otras versiones (1)

BACKGROUND: Rucaparib is an orally available potent selective small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP) 1 and 2. Rucaparib induces synthetic lethality in cancer cells defective in the homologous recombination repair pathway including BRCA-1/2. We investigated the efficacy and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Drew, Yvette, Ledermann, Jonathan, Hall, Geoff, Rea, Daniel, Glasspool, Ros, Highley, Martin, Jayson, Gordon, Sludden, Julieann, Murray, James, Jamieson, David, Halford, Sarah, Acton, Gary, Backholer, Zoe, Mangano, Raffaella, Boddy, Alan, Curtin, Nicola, Plummer, Ruth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882768/
https://www.ncbi.nlm.nih.gov/pubmed/27002934
http://dx.doi.org/10.1038/bjc.2016.41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882768/
https://www.ncbi.nlm.nih.gov/pubmed/27002934
http://dx.doi.org/10.1038/bjc.2016.41

Ejemplares similares